AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18609692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated scalpel (US)
Number of subjects: 40
Study 18609692 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery shovel (ES)
Number of subjects: 40
Study 16053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy 1
Number of subjects: 51
Study 16053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy 2
Number of subjects: 51
Study 16053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy 3
Number of subjects: 51
Study 16053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy 4
Number of subjects: 51
Study 12434952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000/microL platelet transfusion threshold
Number of subjects: 159
Study 12434952 — intervention group
Group type: COMPARATOR
Intervention: 20,000/microL platelet transfusion threshold
Number of subjects: 159
Study 12434952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000/microL and 20,000/microL platelet transfusion thresholds
Number of subjects: 159
Study 10484572 — intervention group
Group type: EXPERIMENTAL
Intervention: OC E + P
Number of subjects: 9
Study 10484572 — intervention group
Group type: EXPERIMENTAL
Intervention: OC P
Number of subjects: 9
Study 10484572 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 9
Study 10484572 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase
Number of subjects: 9
Study 10484572 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma 17beta-estradiol concentration
Number of subjects: 9
Study 8835619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at a dose of 5 mg/kg body weight in addition to insulin therapy
Number of subjects: 22
Study 8835619 — intervention group
Group type: COMPARATOR
Intervention: Control group (insulin therapy only)
Number of subjects: 22
Study 2363545 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical complications (bronchitis)
Number of subjects: 146
Study 2363545 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological complications (atelectasis)
Number of subjects: 146
Study 2363545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxaemia (PaO2 less than 70 mmHg)
Number of subjects: 146
Study 7402803 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and extended postpartum contact
Number of subjects: 321
Study 7402803 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional home visits
Number of subjects: 321
Study 7402803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 321
Study 31233129 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug disposal bag provision
Number of subjects: 202
Study 31233129 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative discharge instructions only (Control)
Number of subjects: 202
Study 28054389 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level exposures (HLE) at 100,000 cm-3
Number of subjects: 52
Study 28054389 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level exposures (LLE) at particle background (3000 cm-3)
Number of subjects: 52
Study 28054389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HLE and LLE
Number of subjects: 52
Study 28054389 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 52
Study 25488504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic care intervention consisting of a primary care provider (PCP) brief intervention, referral to addiction services, and ongoing support from a care manager (CM) for 6 months
Number of subjects: 82
Study 25488504 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 82
Study 23921777 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Brief Lifestyle Counseling
Number of subjects: 390
Study 23921777 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 390
Study 23921777 — intervention group
Group type: COMPARATOR
Intervention: Brief Lifestyle Counseling
Number of subjects: 390
Study 21292760 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 1041
Study 21292760 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 1041
Study 21292760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (as-needed β-agonist)
Number of subjects: 1041
Study 19681417 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment strategy (10 manual breaths with peak inspiratory pressure of 40 cmH2O plus positive end-expiratory pressure of 15 cmH2O)
Number of subjects: 50
Study 19681417 — intervention group
Group type: COMPARATOR
Intervention: Control group (tidal volume 10 ml/kg with no positive end-expiratory pressure)
Number of subjects: 50
Study 17475552 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (n=15)
Number of subjects: 27
Study 17475552 — intervention group
Group type: COMPARATOR
Intervention: Untrained (n=12)
Number of subjects: 27
Study 15213528 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlow palatoplasty
Number of subjects: 30
Study 11576414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine and levamisole (combination treatment)
Number of subjects: 44
Study 11576414 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (control)
Number of subjects: 44
Study 9531852 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8034203 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR) 250 mg 4 times daily (1 g/day), UK, n = 19 patients
Number of subjects: 104
Study 8034203 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 3 times daily (900 mg/day), FRG and Belgium, n = 55
Number of subjects: 104
Study 8034203 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR) 300 mg 4 times daily (1,200 mg/day), The Netherlands, n = 30
Number of subjects: 104
Study 8034203 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 104
Study 8034203 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐(beta‐hydroxyethyl)‐rutosides (HR)
Number of subjects: 104
Study 2808264 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide awareness curriculum provided to 215 students
Number of subjects: 471
Study 2808264 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide awareness curriculum
Number of subjects: 471
Study 786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 20 mg
Number of subjects: 329
Study 786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 40 mg
Number of subjects: 329
Study 786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 60 mg
Number of subjects: 329
Study 786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol 80 mg
Number of subjects: 329
Study 786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol with dihydralazine and hydrochlorothiazide
Number of subjects: 329
Study 786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine 30 mg
Number of subjects: 329
Study 786673 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 30 mg
Number of subjects: 329
Study 30950450 — intervention group
Group type: EXPERIMENTAL
Intervention: Various adjuvant treatments including locoregional and systemic therapies as per trials mentioned (MAGIC, Intergroup 0116, ACTS‐GC, CLASSIC, ARTIST, CRITICS)
Number of subjects: 0
Study 28159608 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Tb skin test
Number of subjects: 979
Study 28159608 — intervention group
Group type: COMPARATOR
Intervention: TST
Number of subjects: 979
Study 25863779 — intervention group
Group type: COMPARATOR
Intervention: MMP‐13 in patients with alcoholic liver cirrhosis (stage A, B, C)
Number of subjects: 60
Study 25863779 — intervention group
Group type: COMPARATOR
Intervention: Glutamic acid and glutamine concentrations in patients with alcoholic liver cirrhosis (stage A, B, C)
Number of subjects: 60
Study 25863779 — intervention group
Group type: COMPARATOR
Intervention: Plasma levels of valine, isoleucine, leucine, and tryptophan in patients with alcoholic liver cirrhosis (stage C)
Number of subjects: 60
Study 25863779 — intervention group
Group type: COMPARATOR
Intervention: MMP‐1 in patients with alcoholic liver cirrhosis
Number of subjects: 60
Study 23211475 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone for 16 weeks
Number of subjects: 30
Study 23211475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21255472 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (intragastric infusion)
Number of subjects: 12
Study 21255472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (intragastric infusion)
Number of subjects: 12
Study 21255472 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Sweeteners (AS: aspartame, acesulfame K, sucralose) (intragastric infusion)
Number of subjects: 12
Study 21255472 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-deoxy-d-glucose (intragastric infusion)
Number of subjects: 12
Study 21255472 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 12
Study 18495285 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.1mg
Number of subjects: 226
Study 18495285 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.3mg
Number of subjects: 226
Study 18495285 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.6mg
Number of subjects: 226
Study 18495285 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.9mg
Number of subjects: 226
Study 15798546 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg) and succinylcholine (0.75 mg/kg)
Number of subjects: 25
Study 15798546 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.15 mg/kg) and succinylcholine (0.75 mg/kg)
Number of subjects: 25
Study 15798546 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Propofol and Etomidate)
Number of subjects: 25
Study 14514937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mg once daily in the morning (09.00 hours)
Number of subjects: 121
Study 14514937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mg once daily in the evening (21.00 hours)
Number of subjects: 121
Study 14514937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 10651681 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (6% end-tidal concentration in oxygen for 30 min)
Number of subjects: 30
Study 10651681 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (1.1% end-tidal concentration in oxygen for 30 min)
Number of subjects: 30
Study 10651681 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of 10 patients with pulmonary artery catheters
Number of subjects: 30
Study 8673580 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: simulated wrestling tournament, four 5‐min wrestling bouts after a 5% body weight loss and 17 h repletion period
Number of subjects: 12
Study 8673580 — intervention group
Group type: COMPARATOR
Intervention: Group B: 5% weight loss through energy restriction (1,141 kcal/day), exercise, fluid restriction, and dehydration methods (sauna) > 72 h
Number of subjects: 12
Study 1631878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride 0.5% solution, 10 ml/h
Number of subjects: 24
Study 1631878 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% solution, 10 ml/h
Number of subjects: 24
Study 6397856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramoxine hydrochloride 1% and hydrocortisone acetate 1% in muco-adhesive foam base
Number of subjects: 40
Study 6397856 — intervention group
Group type: COMPARATOR
Intervention: Simple aqueous foam (B.P.)
Number of subjects: 40
Study 31795359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense weekly paclitaxel (80 mg/m2) and low-dose triweekly cisplatin (20 mg/m2)
Number of subjects: 32
Study 29466093 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention
Number of subjects: 588
Study 29466093 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 588
Study 27206459 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet access with IT support
Number of subjects: 118
Study 24614605 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMT)
Number of subjects: 0
Study 22681227 — intervention group
Group type: EXPERIMENTAL
Intervention: K101
Number of subjects: 493
Study 22681227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 20453678 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 59
Study 20453678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 18820248 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarming using the Bair Paws system for 60 min at 38 degrees C
Number of subjects: 68
Study 18820248 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewarming using the Bair Paws system
Number of subjects: 68
Study 18820248 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 68
Study 16028386 — intervention group
Group type: EXPERIMENTAL
Intervention: Profenid administered per rectum (100 mg)
Number of subjects: 40
Study 16028386 — intervention group
Group type: EXPERIMENTAL
Intervention: Profenid administered intravenously (100 mg)
Number of subjects: 40
Study 12601511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvicol implant (n=74)
Number of subjects: 142
Study 12601511 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT) (n=68)
Number of subjects: 142
Study 12601511 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 142
Study 12601511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvicol implant
Number of subjects: 142
Study 10684389 — intervention group
Group type: COMPARATOR
Intervention: Patch testing
Number of subjects: 401
Study 10684389 — intervention group
Group type: COMPARATOR
Intervention: Day of application
Number of subjects: 401
Study 10684389 — intervention group
Group type: COMPARATOR
Intervention: Day of reading
Number of subjects: 401
Study 10684389 — intervention group
Group type: COMPARATOR
Intervention: Positive patch tests
Number of subjects: 401
Study 9248868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 26
Study 9248868 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 26
Study 8403908 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestrel-based (NG) OC
Number of subjects: 892
Study 8403908 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone acetate-based (NA) OC
Number of subjects: 892
Study 3861138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2-gel (0.5 mg)
Number of subjects: 38
Study 3861138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3861138 — intervention group
Group type: COMPARATOR
Intervention: PGE2 vaginal suppositories (2.0 mg)
Number of subjects: 38
Study 31960537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led structured counselling session (30 minutes before and 24 hours after PCI)
Number of subjects: 80
Study 31960537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led structured counselling session
Number of subjects: 80
Study 31960537 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-procedure information (control group)
Number of subjects: 80
Study 29950742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 34
Study 29950742 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional hemostasis)
Number of subjects: 34
Study 27562067 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (85% HRmax)
Number of subjects: 121
Study 27562067 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (65% HRmax)
Number of subjects: 121
Study 27562067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (45% HRmax)
Number of subjects: 121
Study 27562067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 27562067 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups
Number of subjects: 121
Study 25298575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 mg, 5 mg, 10 mg)
Number of subjects: 60
Study 25298575 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate (25 mg, 50 mg, 100 mg)
Number of subjects: 60
Study 23171672 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum strategy (MS): dissemination of the IBSM program
Number of subjects: 420
Study 23171672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate strategy (IS): MS + start-up support for professionals
Number of subjects: 420
Study 23171672 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended strategy (ES): IS + additional training and ongoing support for professionals
Number of subjects: 420
Study 23171672 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 420
Study 23171672 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness measurements
Number of subjects: 420
Study 21134821 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy doublet fluoropyrimidine (5-FU or capecitabine) plus cisplatin (FP) every three weeks
Number of subjects: 100
Study 21134821 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 100
Study 18315508 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 10
Study 18315508 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 10
Study 15948255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole combined with tepreton (group A)
Number of subjects: 3
Study 15948255 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (group B)
Number of subjects: 3
Study 15948255 — intervention group
Group type: COMPARATOR
Intervention: Tepreton (group C)
Number of subjects: 3
Study 12578781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 40 mg, administered orally, three times daily for 4 weeks
Number of subjects: 27
Study 12578781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules filled with 40 mg fructose)
Number of subjects: 27
Study 10547209 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin added to glibenclamide therapy during phase I (4 months)
Number of subjects: 175
Study 10547209 — intervention group
Group type: COMPARATOR
Intervention: Placebo after sulphonylurea withdrawal during phase II (1-4 months)
Number of subjects: 175
Study 10547209 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide during phase II (1-4 months)
Number of subjects: 175
Study 10547209 — intervention group
Group type: EXPERIMENTAL
Intervention: SU responders defined by protocol (FBG increase > or =40%)
Number of subjects: 175
Study 10547209 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 175
Study 10547209 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-antibody status
Number of subjects: 175
Study 8915222 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 10
Study 8915222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1801688 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF after chemotherapy
Number of subjects: 36
Study 1801688 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF as a priming agent 24 hours prior to chemotherapy
Number of subjects: 36
Study 1801688 — intervention group
Group type: COMPARATOR
Intervention: Control group (historic)
Number of subjects: 36
Study 6335039 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 7
Study 6335039 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 7
Study 30842213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX) - 60 min at 75% of age-predicted maximum heart rate
Number of subjects: 22
Study 30842213 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NE)
Number of subjects: 22
Study 30842213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX)
Number of subjects: 22
Study 30842213 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (EX) and No exercise (NE)
Number of subjects: 22
Study 29166336 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis (2 × 450 mg/d for 100 days)
Number of subjects: 299
Study 29166336 — intervention group
Group type: COMPARATOR
Intervention: Preemptive treatment (2 × 900 mg/d initiated at viral load of 400 CMV copies/mL or greater)
Number of subjects: 299
Study 29166336 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis
Number of subjects: 299
Study 29166336 — intervention group
Group type: COMPARATOR
Intervention: Preemptive treatment
Number of subjects: 299
Study 27362855 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 74
Study 25199046 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy
Number of subjects: 74
Study 25199046 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure group therapy
Number of subjects: 74
Study 25199046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype confirmation concerns (SCC)
Number of subjects: 74
Study 25199046 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment symptom severity, race, age, gender
Number of subjects: 74
Study 23253305 — intervention group
Group type: EXPERIMENTAL
Intervention: Third wave cognitive therapy
Number of subjects: 84
Study 23253305 — intervention group
Group type: COMPARATOR
Intervention: Mentalization-based therapy
Number of subjects: 84
Study 20010133 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 48
Study 20010133 — intervention group
Group type: COMPARATOR
Intervention: Sham PRT
Number of subjects: 48
Study 20010133 — intervention group
Group type: COMPARATOR
Intervention: High-intensity cycling
Number of subjects: 48
Study 20010133 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (PRT + cycling)
Number of subjects: 48